GlaxoSmithKline plc (GSK.L)
-LSE 1,544.50 
14.00(0.90%) 8:03AM EDT
| Prev Close: | 1,558.50 |
|---|
| Open: | 1,555.00 |
|---|
| Bid: | 1,544.50 |
|---|
| Ask: | 1,545.00 |
|---|
| 1y Target Est: | 1,877.56 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1,537.00 - 1,555.50 |
|---|
| 52wk Range: | 556.50 - 2,076.00 |
|---|
| Volume: | 2,669,683 |
|---|
| Avg Vol (3m): | 5,826,090 |
|---|
| Market Cap: | 74.83B |
|---|
| P/E (ttm): | 1,890.45 |
|---|
| EPS (ttm): | 0.82 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in GBp.
Headlines
- What This Top Dividend Portfolio Is Holding Now: GlaxoSmithKline plc, Centrica PLC and Vodafone Group plcat Motley Fool(Wed 7:38AM EDT)
- PRESS DIGEST - Wall Street Journal - Oct 1Reuters(Tue, Oct 1)
- Investors should seek to add ratios to new pay regimeat Financial Times(Mon, Sep 30)
- Corruption Currents: From Historic Phone Calls to Data Havens Seek Businessat The Wall Street Journal(Mon, Sep 30)
- Aspen to pay £700m for GlaxoSmithKline's blood-clotting drugsat Financial Times(Mon, Sep 30)
- Aspen Acquires GSK Injectable Thrombosis Brands for $970 Millionat Bloomberg(Mon, Sep 30)
- [$$] GSK Sells Thrombosis Brandsat The Wall Street Journal(Mon, Sep 30)
- Li Keqiang Says China Can Reach its Economic Targets This Yearat Bloomberg(Mon, Sep 30)
- GSK sells thrombosis drugs to Aspen for $1 billionReuters(Mon, Sep 30)
- Global Cancer Fund Needed to Fight Surging Cases in Poor Nationsat Bloomberg(Mon, Sep 30)
- AstraZeneca CEO gets two cheers after first year in jobReuters(Mon, Sep 30)
- GlaxoSmithKline plc Has Cracked Researchat Motley Fool(Mon, Sep 30)
- Roche’s Kadcyla Beats Herceptin in Delaying Cancer Progressionat Bloomberg(Fri, Sep 27)
- Exclusive: Nestle weighing sale of PowerBar - sourcesReuters(Thu, Sep 26)
- The Buffett Bull Case For GlaxoSmithKline plcat Motley Fool(Thu, Sep 26)
Key Statistics
| Forward P/E (1 yr): | 0.12 |
|---|
| P/S (ttm): | 285.83 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 115.34 |
|---|
| Quarterly EPS Est
(Sep-13)
: | 28.89 |
|---|
| Mean Recommendation*: | 2.6 |
|---|
| PEG Ratio (5 yr expected): | 1.81 |
|---|
Business Summary
GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide.
View More